Ibrutinib and novel BTK inhibitors in clinical development

Overview of attention for article published in Journal of Hematology & Oncology, August 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs: 1 blog
twitter: 1 X user

patent: 8 patents

Citations

dimensions_citation: 197 Dimensions

Readers on

mendeley: 240 Mendeley

Summary Blogs X Patents Dimensions citations

So far, Altmetric has seen 8 patents that reference this research output.

SSEA-4 BINDING MEMBERS

Application WO-2021044039-A1

World Intellectual Property Organisation (WIPO)

COMBINATION PRODUCT OF BCL-2 INHIBITOR OR BCL-2/BCL-XL DUAL INHIBITOR AND BTK INHIBITOR…

Application WO-2020024916-A1

World Intellectual Property Organisation (WIPO)

HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING CHRONIC…

Application EP-3445364-A4

European Patent Office

METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE…

Application WO-2018102785-A2

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 4 additional patents.